Verrica Pharmaceuticals warns of substantial doubt about its ability to continue as a going concern as its cash runway only extends into late 2027.
SEC EDGAR, 2026-11-13: 10-Q — "substantial doubt"
Verrica Pharmaceuticals warns of substantial doubt about its ability to continue as a going concern as its cash runway only extends into late 2027.
Company: Verrica Pharmaceuticals Inc. (VRCA) Filed: 2026-11-13, 10-Q (Item none) Phrase: "substantial doubt" — "Based on the current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, the Company has concluded that substantial doubt exists regarding its ability to continue as a going concern within one year after the date these consolidated financial statements are issued." What the filing says: Verrica Pharmaceuticals has concluded that there is substantial doubt regarding its ability to continue as a going concern. As of September 30, 2026, the company had cash of $14.4 million, an accumulated deficit of $360.2 million, and cash outflows from operations of $27.5 million for the first nine months of 2026. Although Verrica achieved milestones on October 22, 2026, that unlocked an additional $15 million of borrowing capacity under its credit agreement with PD Joint Holdings, LLC (bringing total availability to $27.5 million, of which $12.5 million has been funded), the company states this capacity is only sufficient to extend its cash runway into the fourth quarter of 2027, and this estimate excludes potential clinical trial costs for its VP-315 program. The company plans to address its liquidity needs through further credit draws, equity offerings, debt financing, collaborations, strategic alliances, or licensing arrangements. Two ways it goes: A. The company secures additional equity, debt, or collaboration funding to extend its runway and support its clinical trials. B. The company fails to raise capital or draw sufficient funds, forcing it to delay, reduce, or eliminate its commercialization and development programs. Next date: Fourth quarter of 2027, the estimated limit of the company's cash runway assuming full credit draws and no VP-315 clinical trial costs. Watch: SEC filings announcing new equity offerings, debt financing, collaborations, or additional draws under the PD Credit Agreement. Tags: going concern